Vertex Pharmaceuticals as a secret favorite?
Vertex Pharmaceuticals as an insider favorite?
Vertex Pharmaceuticals is no longer such an insider tip - after all, the stock is already a component of many successful biotech funds. Nevertheless, some investors may not yet be completely familiar with the stock. Vertex also has a monopoly position in the biotech sector when it comes to the treatment of cystic fibrosis. In the second quarter, the Group was already able to increase sales of its proprietary CF drug by six percent year-on-year to USD 2.65 billion.
Vertex is also working on an improved therapy for the disease. Sales could therefore soon grow exponentially. The company is also active in the field of genetic research. Of particular interest, however, is the drug Suzetrigin, which is intended to relieve acute pain and was submitted for approval by the FDA at the beginning of the year. The drug could be an alternative with blockbuster potential, especially for opioids with similar effects, which are controversial due to their numerous side effects. An investment in October could therefore still be worthwhile before the biotech shares report the next breakthroughs.
BÖRSELl ONLINE
https://www.vrtx.com/our-company/
